Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial

I M Bowler, B Kelman, D Worthington, J M Littlewood, A Watson, S P Conway, S W Smye, S L James, T A Sheldon

Abstract

Objective—To assess the benefit of nebulised amiloride added to the standard inpatient treatment of a respiratory exacerbation in cystic fibrosis.

Design—Prospective, randomised, double blind, placebo controlled trial.

Subjects—27 cystic fibrosis patients (mean age 12.8 years).

Setting—Two hospitals in Leeds, UK.

Results—Both forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC) showed improvements over the course of treatment, although there was no difference in respiratory function between the two groups at any of three time periods during the study. The time to reach peak FVC was significantly reduced in the amiloride group (4.2 v 7.6 days; 95% CI 0.4 to 6.4 days), but not in the time to reach peak FEV₁ (5.7 v 7.9 days; 95% CI -1.2 to 5.6 days).

Conclusions—Amiloride did not result in a greater overall improvement in respiratory function. There was a suggestion that it may have an effect on the rate of improvement, and thus may possibly influence the duration of treatment. This hypothesis deserves further evaluation.

(*Arch Dis Child* 1995; 73: 427-430)

Keywords: cystic fibrosis, amiloride, randomised controlled trial.

Regional Paediatric Cystic Fibrosis Unit, St James's University Hospital, Leeds
I M Bowler
B Kelman
D Worthington
J M Littlewood

Regional Adult Cystic Fibrosis Unit, Seacroft Hospital, Leeds
A Watson
S P Conway

Department of Medical Physics, St James's University Hospital, Leeds
S W Smye

Department of Pharmacy, University of Brighton
S L James

NHS Centre for Reviews and Dissemination, University of York
T A Sheldon

Correspondence to:
Dr I M Bowler, University Department of Child Health, G Level - Centre Block, Southampton General Hospital, Tremona Road, Southampton SO16 6YD.

Accepted 25 May 1995

Patients and methods

Patients were recruited from patients attending the Leeds cystic fibrosis clinic at St James's University Hospital (children) and Seacroft Hospital (adults). They had classical features of cystic fibrosis and two measurements of sweat sodium and chloride concentrations of greater than 60 mmol/l.

All patients admitted for a course of inpatient intravenous antibiotic treatment were eligible for inclusion into the study unless they were unable to perform respiratory function tests (usually <6 years old), had bronchospasm as a principal feature of their respiratory exacerbation, were thought to have allergic bronchopulmonary aspergillosis likely to require treatment with corticosteroids, or were likely to have a general anaesthetic during the study period. The ability to expectorate sputum was not a criterion for entry into the study.

All patients received a standard treatment protocol,⁸ including intravenous antibiotics (based on bacterial sensitivities), physiotherapy, bronchodilators, and nutritional advice from the time of admission.

Informed consent for the study was obtained from patients and parents on the day of admission. Stratified randomisation was used to improve the comparability of the groups. Patients were allocated a consecutive trial code number within four strata, based on age (< or ≥12 years) and forced vital capacity (< or ≥75% of predicted). Based on these codes the pharmacy department at St James's University Hospital referred to a randomised treatment plan and dispensed either amiloride hydrochloride nebuliser solution or placebo. The randomisation schedule was compiled by the study group statistician (TAS) and supplied confidentially to the pharmacy department. Both the patients and the remaining investigators were blinded to the treatment allocation.

The amiloride hydrochloride solution 5×10^{-3} M (0.15% w/v) in 0.3% saline (approximately pH 7.0) was prepared by the pharmacy department from amiloride hydrochloride powder (Cox Pharmaceuticals). The placebo used was 0.3% saline solution which had the same osmolality as the amiloride solution. The solutions were supplied as individual doses in identical darkened glass bottles which were stored at room temperature. All patients received 4.0 ml three times daily. The solutions were nebulised using a Medix Maxi III compressor and a System 22 nebuliser (Medic-Aid) with a mouthpiece. Treatment was continued for the duration of

Ion transport defects in cystic fibrosis include excessive sodium and water absorption across the respiratory epithelium, which reduces the surface epithelium water layer and increases the viscosity of secretions.^{1,2} Mucociliary clearance may thus be impaired, making respiratory infection more likely. Studies have shown that amiloride can inhibit this excessive absorption of sodium and water^{2,3} and it has been found to improve mucociliary clearance and cough clearance in cystic fibrosis patients.^{4,5} In a pilot study of long term amiloride treatment, Knowles *et al* showed that regular nebulised amiloride could reduce the speed of deterioration in respiratory function.⁶ However, others found no such benefit.⁷

In view of the possible short term benefits of inhaled amiloride, we planned a double blind randomised controlled trial to investigate the effect of nebulised amiloride when used in addition to standard intravenous antibiotic treatment for a respiratory exacerbation.

Monitoring of progress.

the inpatient treatment course (usually two weeks).

MONITORING OF PROGRESS

Baseline measurements of respiratory function, clinical score (see below), and sputum purulence and viscoelasticity were made on the morning after admission, before starting amiloride or placebo therapy. Respiratory function was also measured before and after the first dose of amiloride or placebo to ensure that bronchospasm did not occur.

Respiratory function was measured daily, 45 minutes after the administration of amiloride or placebo (during which time the patient received physiotherapy, see the figure), using a Micro spirometer (Micro Medical). Measurements of forced expiratory volume in one second (FEV₁) and forced vital capacity (FVC) were expressed as a percentage of expected values according to age, height, and sex.

A composite clinical score (assessed on cough, sputum volume and colour, respiratory rate, pulse rate, and presence of added sounds on chest auscultation) was also recorded daily. Each variable was scored 0–3 and the sum noted.⁸

Sputum samples were collected twice weekly when possible. Purulence was estimated by simple grading colour against a reference chart

Table 1 Patients' baseline data

	Amiloride (n=13)		Placebo (n=14)		p Value
	Mean	Range	Mean	Range	
Age (years)	13.8	7.9–27.7	11.8	6.0–21.1	0.3
Male (number (%))	6 (46)		5 (36)		
Weight (kg)	36.2	20.5–62.1	33.3	20.1–55.9	0.6
Weight/height (% predicted)	92.6	74.0–111.6	90.9	69.7–112.0	0.7
FEV ₁ (% predicted)	52.8	13.0–88.0	55.9	21.0–111.0	0.8
FVC (% predicted)	63.5	12.0–102.0	64.1	23.0–114.0	1.0
Clinical score	7.9	4.0–15.0	7.4	2.0–13.0	0.8
IgG (g/l)	13.9	9.3–25.4	14.5	5.4–26.7	0.8
Sputum purulence	2.5	2–3	2.2	1–3	0.4
Sputum viscoelasticity (G' at 10 Hz) (N/m ²)	18.6	4.3–47.0	13.5	2.5–33.2	0.4

and was scored 0–3. Sputum samples for viscoelasticity measurement were snap frozen in liquid nitrogen and stored in a refrigerator. They were later transported on dry ice to the University of Brighton. Dynamic storage modulus (G') and loss modulus (G'') were measured using a Carri-med controlled stress rheometer, using a cone and plate geometry, a high sensitivity transducer, and oscillatory testing within the linear viscoelastic region in the range 1–10 Hz.⁹

The study protocol was approved by the research ethics committee for the two hospitals.

STATISTICAL METHODS

Estimates of the study sample size required were undertaken and it was calculated that 36 patients in each treatment group would be required to detect a 10% additional increase in FVC (percentage predicted), with an 80% power at a 5% significance level. However, we believed that it was more likely that amiloride would result in an increased rate in improvement, rather than an augmentation in the increase in respiratory function which might be achieved by a course of intravenous antibiotics. It was for this reason that these data were measured daily.

Data were analysed on a personal computer using the SPSS/PC+ software package. The repeated measurements of FEV₁, FVC, and clinical score were averaged over three time periods. The means and medians of these were compared by unpaired *t* tests or Mann-Whitney U tests respectively. Multivariate analysis of variance (MANOVA) was also used to compare these variables in order to take account of correlation of serial measurements over time.¹⁰ In addition a comparison of the time to peak lung function reading was carried out which is also an appropriate method for analysing serial measurements on the same patients.¹¹

Results

PATIENTS

Twenty seven patients (mean age 12.8 years (range 6.0–27.7 years), 11 males, 16 females) were recruited into the study. The groups were

Table 2 Sputum bacteriology (number of patients)

	Amiloride	Placebo
<i>Pseudomonas aeruginosa</i>	7	9
<i>Burkholderia cepacia</i>	1	0
<i>Stenotrophomonas maltophilia</i>	1	2
<i>Staphylococcus aureus</i>	4	4
<i>Haemophilus influenzae</i>	2	2
<i>Aspergillus fumigatus</i>	2	3

Table 3 Antibiotic treatment (number of patients)

	Amiloride	Placebo
Ceftazidime	5	6
Ureidopenicillins (piperacillin, azlocillin)	9	5
Aminoglycosides (tobramycin, amikacin)	11	12
Colomycin (IV)	2	2
Ciprofloxacin (oral)	2	2
Others (temocillin, imipenen, aztreonam, cefotaxime, ampicillin)	6	2

Table 4 Differences between respiratory function values at the three time periods

Time period	No (Am/Pl)	Mean FEV ₁ (% predicted)				Mean FVC (% predicted)			
		Amiloride	Placebo	Difference (95% CI)	p Value‡	Amiloride	Placebo	Difference (95% CI)	p Value‡
Q1	13/14	55.5	59	3.3 (-23.3 to 16.6)	0.7	69	67	-1.8 (-15.6 to 4.2)	0.7
Q2	12/14	59	64	4.8 (-24.0 to 14.4)	0.6	74	73	-0.5 (-19.8 to 23.5)	1.0
Q3	9/9	57.5	62	4.4 (-27.9 to 19.0)	0.86	69	71	2.1 (-20.1 to 21.1)	0.85

CI=confidence interval; FEV₁=forced expiratory volume in one second; FVC=forced vital capacity; Am=amiloride; Pl=placebo. ‡Unpaired *t* test.

comparable with respect to age, anthropometry, baseline respiratory function, clinical score,⁸ and serum immunoglobulin G concentration (table 1). Sputum viscoelasticity and purulence were comparable between the groups at baseline (table 1); however, insufficient data were collected during the trial to use these variables to assess the efficacy of amiloride. There were no material differences in the patients' sputum bacteriology (table 2) or the antibiotics received (table 3) between the two groups.

Twenty two patients completed the study. Five patients did not complete the study protocol: two patients in the amiloride treatment group developed bronchospasm and were withdrawn from the study; the others were in the placebo group. Of these three patients, one developed chickenpox, one elected to withdraw from the study without giving a reason, and a third was withdrawn because of non-compliance with the study protocol.

RESPIRATORY FUNCTION AND CLINICAL SCORE

The repeated measurements of these data were averaged over three time periods; the first four days (Q1), the second five days (Q2), and the final six days (Q3). There was no difference between the two arms of the study for mean FEV₁ or FVC in any of the three time periods (table 4). Non-parametric analysis of medians showed similar results. A number of patients were discharged between periods Q2 and Q3, and thus Q3 contained a biased selection of patients who had made less improvement. This explains the reduction in average respiratory function between periods Q2 and Q3.

MANOVA for repeated measures showed a significant increase in the FEV₁ ($p=0.006$) and FVC ($p=0.003$) over the three time periods (χ^2 test). However, there was no significant difference between the trend of improvement between the treatment and control group (FEV₁ $p=0.8$; FVC $p=0.7$). This was unlikely to be the result of a lack of power in the study. The time to peak FEV₁ and FVC for each patient was determined (table 5). There was a small but statistically significant reduction in time to peak FVC in the amiloride group. Patients who withdrew from the study were included in the estimates of time to peak

respiratory function; however, the difference in the time to peak FVC was still statistically significant even if these subjects were excluded from the analysis.

There was no difference in clinical score at each of the three time periods. MANOVA again showed a significant improvement over time ($p<0.001$), but no difference between the groups ($p=0.8$). There were no significant changes in serum sodium or potassium in either group.

Discussion

Nebulised amiloride has been found to improve cough clearance and mucociliary clearance in cystic fibrosis patients,^{4,5} and other studies have shown that it can increase the quantity of sputum expectorated.^{12,13} It has antibacterial activity against *Pseudomonas* species¹⁴ and synergy with tobramycin against *Burkholderia* (formerly *Pseudomonas*) *cepacia*.¹⁵ For these reasons we postulated that nebulised amiloride may be of benefit when used in the treatment of acute respiratory exacerbations.

Most patients are returned to their 'best' clinical condition by a course of intravenous antibiotics. We predicted that any benefit of additional amiloride would be to increase the rate of improvement in respiratory function, rather than its extent, but this made pretrial estimates of the required study sample size more difficult to determine. However, there was a considerable increase in the use of home intravenous antibiotic treatment during the period in which the study was conducted, and significantly fewer patients than planned for were recruited. This reduced the power of the study to detect differences as statistically significant, and thus the study should be considered as generating a hypothesis rather than proving one.

We have shown that the additional use of nebulised amiloride in cystic fibrosis patients receiving a standard inpatient intravenous antibiotic course did not result in a greater improvement in respiratory function or clinical score than nebulised vehicle alone. However, there was a suggestion that nebulised amiloride may shorten the time to achieve optimal respiratory function (for FVC), which may have implications for the total duration of intravenous antibiotic treatment needed. We believe that these results warrant confirmation in a larger multicentre study.

CONCLUSION

We conclude that nebulised amiloride may be of some benefit to cystic fibrosis patients in

Table 5 Time to peak respiratory function

	Amiloride (n=13)	Placebo (n=14)	Difference (95% CI)	p Value*
Time to peak FEV ₁ (mean No of days)	5.7	7.9	-2.2 (-5.6 to 1.2)	0.19
Time to peak FVC (mean No of days)	4.2	7.6	-3.4 (-6.4 to -0.4)	0.026

*Two sample *t* test.

accelerating the rate of recovery of lung function. However, its place as part of a new generation of specific therapy cystic fibrosis remains to be determined. A recent study has shown that the effect of amiloride may be augmented by the additional use of uridine triphosphate.¹⁶ Future studies should consider evaluation of this combination therapy.

We are grateful to the Cystic Fibrosis Trust for funding IMB.

- 1 Boucher RC, Stutts MJ, Knowles MR, Cantley L, Gatzky JT. Na⁺ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. *J Clin Invest* 1986; **78**: 1245–52.
- 2 Boucher RC, Cotton CU, Gatzky JT, Knowles MR, Yankaskas JR. Evidence for reduced Cl[−] permeability and increased Na⁺ permeability in cystic fibrosis human primary cell cultures. *J Physiol (Lond)* 1988; **405**: 77–103.
- 3 Knowles MR, Gatzky JT, Boucher RC. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. *N Engl J Med* 1981; **305**: 1489–95.
- 4 Köhler D, App E, Schmitz-Schumann M, Würtemburger G, Matthys H. Inhalation of amiloride improves mucociliary and cough clearance in patients with cystic fibrosis. *Eur J Respir Dis* 1986; **69** (suppl 146): 319–26.
- 5 App E, King M, Helfrieder R, Köhler D, Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. *Am Rev Respir Dis* 1990; **141**: 605–12.
- 6 Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. *N Engl J Med* 1990; **322**: 1189–94.
- 7 Graham A, Hasani A, Alton EFWF, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. *Eur Respir J* 1993; **6**: 1243–8.
- 8 Conway SP, Miller MG, Ramsden C, Littlewood JM. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin and netilmicin and ticarcillin. *Acta Paediatr Scand* 1985; **74**: 107–13.
- 9 El-Hariri LM, Martin GP, Marriott C. The effect of sodium taurodeoxycholate on the rheological properties of pig native and purified gastric mucus [Abstract]. *J Pharmacol* 1989; **41**: 75P.
- 10 Altman DG. *Practical statistics for medical research*. London: Chapman and Hall, 1991: chapter 12.
- 11 Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. *BMJ* 1990; **300**: 230–5.
- 12 Lindemann H, Becker T, Bittner P, Boldt A, Hofmann T, Schwandt HJ. Elimination of secretions in CF patients under amiloride inhalation. [In German.] *Pneumologie* 1990; **44**: 1148–50.
- 13 Riedler J, Huttegger I. Pilot study of amiloride inhalation in children with cystic fibrosis. [In German.] *Klin Padiatr* 1992; **204**: 158–62.
- 14 Cohn RC, Rudzienski L, Putnam RW. In vitro antimicrobial activity of amiloride analogs against pseudomonas. *Chemotherapy* 1992; **38**: 232–7.
- 15 Cohn RC, Jacobs M, Aronoff SC. In vitro activity of amiloride combined with tobramycin against pseudomonas isolates from patients with cystic fibrosis. *Antimicrob Agents Chemother* 1988; **32**: 395–6.
- 16 Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelial of patients with cystic fibrosis. *N Engl J Med* 1991; **325**: 533–8.